Literature DB >> 28295508

Pharmacological treatment for COPD; GOLD 2017 changes direction.

Dave Singh1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28295508      PMCID： PMC5401983          DOI： 10.1111/bcp.13212

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  17 in total

Review 1.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.

Authors:  Jørgen Vestbo; Suzanne S Hurd; Alvar G Agustí; Paul W Jones; Claus Vogelmeier; Antonio Anzueto; Peter J Barnes; Leonardo M Fabbri; Fernando J Martinez; Masaharu Nishimura; Robert A Stockley; Don D Sin; Roberto Rodriguez-Roisin
Journal:  Am J Respir Crit Care Med       Date:  2012-08-09       Impact factor: 21.405

2.  Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.

Authors:  Dave Singh; Alberto Papi; Massimo Corradi; Ilona Pavlišová; Isabella Montagna; Catherine Francisco; Géraldine Cohuet; Stefano Vezzoli; Mario Scuri; Jørgen Vestbo
Journal:  Lancet       Date:  2016-09-01       Impact factor: 79.321

3.  Susceptibility to exacerbation in chronic obstructive pulmonary disease.

Authors:  John R Hurst; Jørgen Vestbo; Antonio Anzueto; Nicholas Locantore; Hana Müllerova; Ruth Tal-Singer; Bruce Miller; David A Lomas; Alvar Agusti; William Macnee; Peter Calverley; Stephen Rennard; Emiel F M Wouters; Jadwiga A Wedzicha
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

4.  Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.

Authors:  Mark T Dransfield; Jean Bourbeau; Paul W Jones; Nicola A Hanania; Donald A Mahler; Jørgen Vestbo; Andrew Wachtel; Fernando J Martinez; Frank Barnhart; Lisa Sanford; Sally Lettis; Courtney Crim; Peter M A Calverley
Journal:  Lancet Respir Med       Date:  2013-04-12       Impact factor: 30.700

5.  Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.

Authors:  Jadwiga A Wedzicha; Donald Banerji; Kenneth R Chapman; Jørgen Vestbo; Nicolas Roche; R Timothy Ayers; Chau Thach; Robert Fogel; Francesco Patalano; Claus F Vogelmeier
Journal:  N Engl J Med       Date:  2016-05-15       Impact factor: 91.245

6.  Characterisation of COPD heterogeneity in the ECLIPSE cohort.

Authors:  Alvar Agusti; Peter M A Calverley; Bartolome Celli; Harvey O Coxson; Lisa D Edwards; David A Lomas; William MacNee; Bruce E Miller; Steve Rennard; Edwin K Silverman; Ruth Tal-Singer; Emiel Wouters; Julie C Yates; Jørgen Vestbo
Journal:  Respir Res       Date:  2010-09-10

Review 7.  New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives.

Authors:  Dave Singh
Journal:  Br J Clin Pharmacol       Date:  2015-05       Impact factor: 4.335

8.  Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT).

Authors:  Eric D Bateman; Kenneth R Chapman; Dave Singh; Anthony D D'Urzo; Eduard Molins; Anne Leselbaum; Esther Garcia Gil
Journal:  Respir Res       Date:  2015-08-02

Review 9.  A review of national guidelines for management of COPD in Europe.

Authors:  Marc Miravitlles; Claus Vogelmeier; Nicolas Roche; David Halpin; João Cardoso; Alexander G Chuchalin; Hannu Kankaanranta; Thomas Sandström; Paweł Śliwiński; Jaromir Zatloukal; Francesco Blasi
Journal:  Eur Respir J       Date:  2016-01-21       Impact factor: 16.671

10.  Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD.

Authors:  Ian D Pavord; Sally Lettis; Nicholas Locantore; Steve Pascoe; Paul W Jones; Jadwiga A Wedzicha; Neil C Barnes
Journal:  Thorax       Date:  2015-11-19       Impact factor: 9.139
View more
  4 in total

1.  New Treatment Options for COPD: How Do We Decide Phenotypes, Endotypes or Treatable Traits?

Authors:  Ron Balkissoon
Journal:  Chronic Obstr Pulm Dis       Date:  2018-01-18

2.  The efficacy of extrafine beclomethasone dipropionate-formoterol fumarate in COPD patients who are not "frequent exacerbators": a post hoc analysis of the FORWARD study.

Authors:  Dave Singh; Stefano Vezzoli; Stefano Petruzzelli; Alberto Papi
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-11-03

3.  Efficacy of low molecular weight heparin for chronic obstructive pulmonary disease and respiratory failure: A protocol of systematic review of randomized controlled trials.

Authors:  Dejun Zhao; Jun-Fei Feng
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

Review 4.  What Can We Apply to Manage Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Acute Respiratory Failure?

Authors:  Deog Kyeom Kim; Jungsil Lee; Ju Hee Park; Kwang Ha Yoo
Journal:  Tuberc Respir Dis (Seoul)       Date:  2018-01-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.